Time for booster vaccination against pertussis in 10-year-old children;Dags att ge förnyelsedos mot kikhosta till 10-åringarna

Lakartidningen

Volumn 102, Issue 35, 2005, Pages 2394-2398

  Carlsson, Rose Marie ^a,b   Ekholm, Leif ^a   Gothefors, Leif ^c   Granström, Marta ^d   Trolin, Ingrid ^e   Tegnell, Anders ^f  

^a Smittskyddsinstitutet ^*

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c Pediatrik   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e MEDICAL PRODUCTS AGENCY   (Sweden)

^f NATIONAL BOARD OF HEALTH AND WELFARE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 24744466927     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (19)

1. Edwards KM, Decker MD. Pertussis vaccine. In: Plotkin SA, Orenstein WA editors: Vaccines. Philadelphia: PA Saunders Inc; 2004.p. 471-528.
2. Romanus V, Jonsell R, Bergquist SO. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 1987;6:364-71.
3. Socialstyrelsens meddelandeblad nr 23/1982. Information om åtgärder mot och vid kikhosta.
4. SFS 1996:1. Socialstyrelsens allmänna råd om vaccination av barn.
5. Gustafsson L, Hallander HO, Advani A, Carlsson RM, Olin P. Six year report. Pertussis surveillance in Sweden, progress report October 1997-September 2003 with an executive summary. Smittskyddsinstitutets rapportserie 2:2004.
6. Wirsing von König CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002;2:744-50.
7. Trollfors B, Taranger J, Lagergård T, Sundh V, Bryla D, Schneerson R, et al. Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr Infect Dis J 1998;17:196-9.
8. Fine PEM. Community immunity. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadelphia: PA Saunders Inc; 2004.p. 1443-61.
9. van Boven M, Ferguson NM, van Rie A. Unveiling the burden of pertussis. Trends Microbiol 2004;12:116-9.
10. Efficacy trial of acellular pertussis vaccines. Final report 1991-2003. Swedish Institute for Infectious Disease Control (SMI) 04 01 14.
11. Olin P, Carlsson RM, Johansen K, Hallander H, Ljungman M, Svensson Å, et al. Vaccinationsuppföljning. Seroepidemiologisk tvärsnittsstudie 1997. Slutrapport. Smittskyddsinstitutets rapportserie nr 3:2004.
12. Olin P. Svenska barns vaccinskydd. Dags att se över påfyllnadsdoserna för difteri, stelkramp, polio och kikhosta. Läkartidningen 2001;98:3654-7.
13. Euvac.net (homepage on the Internet). Copenhagen: Childhood vaccination schedules (updated 2005 May 4; cited 2005 May 12). http://www.ssi.dk.euvac/
14. Belloni C, de Silvestri A, Tinelli C, Avanzini MA, Marconi M, Strano F, et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 2003;111:1042-5.
15. Tozzi AE, Anemona A, Stefanelli P, Salmaso S, Atti ML, Mastrantonio P, et al. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines. Pediatrics 2001;107:e25.
16. Nilsson L, Faldella G, Jacquet JM, Storsaeter J, Silfverdal SA, Ekholm L. A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age. Scand J Infect Dis 2005;37:221-9.
17. Mallet E, Matisse N, Mathieu N, Langue J, Boisnard F, Soubeyrand B, et al. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6 year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vacccine 2004;22:1415-22.
18. Campins-Martí M, Cheng HK, Forsyth K, Guiso N, Halperin S, Huang LM, et al. Recommendations are needed for adolescent and adult pertussis immunization: rationale and strategies for consideration. Vaccine 2002;20:641-6.
19. Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: A cost-benefit analysis. Clin Infect Dis 2004;39:20-8.